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VaccineThe equine disease strangles, caused by Streptococcus equi, remains a major cause of welfare and eco-
nomic cost to the global horse industry. Here we report the safety, immunogenicity and efficacy of a novel
multi-component chimeric fusion protein vaccine, called Strangvac, when administered to ponies via the
intramuscular route. Across the four studies, Strangvac was safe and induced robust antibody responses
towards the vaccine components in blood serum and the nasopharynx, which were boosted by revacci-
nation up to 12 months after a primary course of 2 vaccinations 4 weeks apart. The vaccine response did
not cross-react with a commercial strangles iELISA, which identifies horses that have been exposed to S.
equi, demonstrating that it was possible to differentiate infected from vaccinated animals (DIVA).
Following challenge with S. equi strain 4047 (Se4047), all 36 control ponies that had received an
adjuvant-only placebo vaccine developed clinical signs of strangles. In contrast, intramuscular vaccina-
tion with Strangvac protected ponies significantly from challenge with Se4047 at two weeks (5 of 16
ponies protected (31%), P = 0.04) and two months (7 of 12 ponies protected (58%), P = 0.0046 (including
pooled control data) after second vaccination. Optimal protection (15 of 16 ponies protected (94%),
P < 0.0001) was observed following challenge at two weeks post-third vaccination. Our data demonstrate
that Strangvac is safe, has DIVA capability and provides a rapid onset of protective immunity against
strangles. We conclude that Strangvac is a valuable tool with which to protect horses from strangles, par-
ticularly during high-risk periods, whilst maintaining the mobility of horse populations as required by
the global equine industry.
 2020 The Authors. Published by Elsevier Ltd. This is an open access article under theCCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Strangles, caused by the Lancefield group C pathogen Strepto-
coccus equi, subsp. equi, (S. equi) remains an endemic disease of
horses around the world with an estimated 600 outbreaks occur-
ring in the UK each year [1]. The disease has important economic
impact through the temporary closure of facilities, cancelled
events and veterinary expenses, with some outbreaks costing over
£225,000. A key factor in the transmission of S. equi from one pop-
ulation of horses to another, is its ability to establish persistent
infections in the guttural pouches or sinuses of a proportion of
horses that have recovered from acute disease [2,3]. Thesepersistently infected carriers exhibit no clinical signs of disease
but can shed and transmit S. equi to other animals with which they
come into direct or indirect contact. Persistently infected horses
can be identified and treated using guttural pouch endoscopy
and by commercially available qPCR tests that enable the detection
of S. equi [4,5]. Quantification of the antibody response to two frag-
ments of S. equi surface proteins, SEQ_2190 and SeM, by iELISA has
a high sensitivity and specificity for the detection horses that have
been exposed to S. equi [6]. The test enables veterinarians to min-
imise the number of horses that require further testing by guttural
pouch endoscopy and lavage. However, it is not usually practical to
screen populations of horses with guttural pouch endoscopy or
serology each time they return from an event where they might
have been inadvertently exposed to S. equi. Therefore, there is a
pressing need to develop a safe and effective vaccine, which is
Table 1
Number of ponies vaccinated with Strangvac or placebo per experiment.
Experiment Number of ponies vaccinated
Strangvac vaccinated Placebo vaccinated
EXP I 12 0
EXP II 16 16
EXP III 12 4
EXP IV 16 16
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entiate infected from vaccinated animals (so-called DIVA).
Natural infection with S. equi typically provides protection from
disease for an estimated 5 years [7] and live attenuated vaccines
have been developed based on this principle, namely Pinnacle (li-
censed for use in the USA and New Zealand) [8] and Equilis StrepE
(licensed for use in the European Union) [9]. These vaccines are
given intranasally and sub-mucosally, respectively, but they have
been associated with adverse reactions and clinical signs of stran-
gles and they are not DIVA compatible [10–13]. We have previ-
ously published the results on the development of a novel DIVA
compatible recombinant fused protein vaccine, Strangvac, which
was administered via the intranasal and subcutaneous routes and
conferred significant levels of protection against experimental
challenge with a virulent strain of S. equi [14,15]. Here we present
data from 4 studies in ponies that measured the safety, immuno-
genicity, onset and duration of immunity following basic vaccina-
tion and the restoration of immunity following re-vaccination with
Strangvac when administered by intramuscular injection.2. Materials and methods
2.1. Bacterial strains used in the study
The recombinant S. equi antigens used in Strangvac were
derived from S. equi strain 1866 (Se1866) [16]. Se4047 was used
as the challenge strain in this study [17]. For challenge experi-
ments in ponies, Se4047 was grown overnight in Todd Hewitt
broth containing 10% foetal calf serum (THBS) in a humidified
atmosphere with 5% CO2 at 37 C, diluted 40-fold in fresh pre-
warmed THBS, further cultivated and harvested at an OD600nm of
0.3 as previously described [14,15].
For gene cloning and for expression of recombinant fusion pro-
teins E. coli strain BL21 was grown at 37 C in Bacto Tryptone with
Yeast extract medium supplemented with kanamycin (final conc.
50 mg/ml).
2.2. Construction and purification of fusion proteins
Strangvac is based on CNE, SclC, SclF, SclI and EAG (fused as
CCE), SEQ_0402 and SEQ_0256 (fused as Eq85) and IdeE generated
from clones where nucleotide sequences were synthesized to
obtain optimal codon choice for E. coli and purified as previously
described [15]. These proteins, with the exception of IdeE, are pre-
dicted to be localised on the bacterial surface and antibodies
against them are assumed to be opsonic and block bacterial adher-
ence to tissue surfaces. The choice of components in Strangvac is
based on previous studies [14]. Briefly, for all proteins a combina-
tion of ammonium sulphate precipitation, hydrophobic interaction
chromatography and ion exchange chromatography was used for
purification [15].
2.3. Immunization of ponies
Ponies between 6 and 12 months of age (n = 56) were vacci-
nated with Strangvac in four separate experiments, EXP I, EXP II,
EXP III and EXP IV, where they were divided into groups as shown
in Table 1. Three additional groups of ponies of the same age (n =
16 + 4 + 16, respectively), one per experiment for EXP II, EXP III and
EXP IV, were vaccinated with a placebo control vaccine containing
only adjuvant. Ponies were maintained at pasture for the duration
of the vaccination phases. Ponies were vaccinated by intramuscu-
lar administration of 2 ml of Strangvac. Each intramuscular dose
contained 106 mg of CCE, 42 mg of Eq85, 32 mg of IdeE and 326 mg
of Matrix C a saponin derived adjuvant, in a 2 ml volume (NovavaxAB, Uppsala, Sweden). Vaccination schedules are shown in Fig. 1.
The vaccination status of all ponies in EXPII, EXPIII and EXPIV
was blinded to study personnel throughout the experimental
phases.
2.4. Nasal swab and blood sampling
Nasal swabs and blood samples were taken pre-vaccination,
pre-challenge and three times a week post-challenge. The nasal
swab comprised a rayon pad on the end of a 30 cm long thin plastic
tube, which was inserted into the nares of the pony to be sampled
until a swallowing reflex was induced, indicating that the swab
had touched the back of the nasopharynx. The plastic tube was
cut and the swab pad placed into 3 ml of PBS, vortexed and then
centrifuged at 1750g, The supernatant was decanted and stored
at 70 C. Blood samples, were drawn from the jugular vein and
allowed to clot at room temperature for 2 h The serum was then
removed and stored at 20 C.
2.5. Quantification of the immune response to vaccination
Serum samples and nasal wash samples were taken at regular
intervals to measure IgG responses by conventional iELISA per-
formed as previously described [14]. Samples were serially diluted
two-fold and the log10 value of the dilution required to obtain an
absorbance value below a cut off threshold of 1.5 (for serum sam-
ples) or 1.0 (for nasal washes) was determined. The amount of IgG
towards the SEQ_2190 and SeM protein fragments used in a com-
mercial dual iELISA for the detection of horses exposed to S. equi
was determined as previously described [6].
2.6. Experimental infection of ponies and clinical assessment
Ponies were divided into groups at random and moved to one of
four rooms within a purpose-built containment unit three days
prior to challenge. A 2 ml culture of Se4047 containing 5  107
cfu was sprayed into each nostril (1  108 cfu per pony in total).
Clinical signs of infection, rectal temperature, and swelling of sub-
mandibular lymph nodes (SMLN) were followed daily for four
weeks or until the time of euthanasia on reaching the humane end-
point of pyrexia and a preference for haylage and water over dried
pelleted food. As a sign of inflammation, fibrinogen levels and neu-
trophil counts were determined, elevated fibrinogen level and neu-
trophil count were defined as a value exceeding the upper 2.5
percentile of the values obtained before challenge [14,18]. Post-
mortem examination was performed on all ponies following
euthanasia. The severity of disease and pathology was quantified
according to a scoring system described previously [18] and sum-
marized below: Retropharyngeal or submandibular lymph node
abscess = 15, Retropharyngeal or submandibular lymph node
microabscess = 10, empyema of guttural pouch = 5, scarring of gut-
tural pouch = 5, enlarged lymph node = 1, Follicular hyperplasia of
guttural pouch = 1. The amount of S. equi DNA present on swabs
taken post-mortem was determined by qPCR as previously
described [4].
Fig. 1. Immunization schedule. Ponies were vaccinated as indicated, followed by experimental infection two weeks (EXP II and EXP IV) or two months (EXP III) after the last
vaccination. Challenged ponies were observed for three weeks or until the time of euthanasia. V1, V2 and V3 indicate the time of first, second and third vaccinations.
C. Robinson et al. / Vaccine 38 (2020) 4861–4868 48632.7. Statistical methods
The Mann Whitney test was used to test the significance of
post-mortem scores. A two-way ANOVA was used to calculate
the significance between pooled post-mortem scores of control
ponies with vaccinates for EXP III. The Wilcoxon rank sum test
was used to compare temperatures, fibrinogen levels, and neu-
trophil counts. The Last Observation Carried Forward method
was used to account for ponies euthanased on welfare grounds
prior to day 8 post-challenge on the assumption that their clinical
signs of disease would have becomemore pronounced. The Fisher’s
exact probability test was used for the comparison of frequencies
over the whole experimental time course. The Kruskal-Wallis test
was used to determine statistical differences between groups of
control ponies.
2.8. Ethical considerations
This work was conducted under the auspices of a Home Office
Project License and following ethical review and approval by the
Animal Health Trust’s Animal Welfare and Ethical Review Body
(RPP 01_08).
3. Results and discussion
3.1. Strangvac was safe for intramuscular injection
Intramuscular vaccination was used throughout these studies
since it is quick, easy and preferred by veterinarians. Table 1 shows
that over the course of the four studies, 56 ponies received a total
of 140 doses of Strangvac and 36 ponies received a total of 87 doses
of the placebo vaccine, which contained adjuvant only. The vacci-
nations were well tolerated throughout the studies with a propor-
tion (12/12, 9/32, 12/16 and 18/32, for Experiments I, II, III and IV
respectively) of ponies in each study showing mild transient clini-
cal signs that resolved completely without veterinary intervention
between one and five days post-vaccination. There was no differ-
ence in the incidence of these mild injection site reaction indica-
tors (heat, pain and swelling) between Strangvac- and placebo
control-vaccinated ponies after the first vaccination (Table 2).However, the incidence of mild injection site reaction indicators
was significantly more frequent in ponies that had been vaccinated
with Strangvac when compared with those vaccinated with the
placebo control vaccine after the second and third vaccinations
(Table 2). Therefore, the occurrence of transient heat, swelling
and pain at the injection site likely reflect the development of an
immune response to the specific protein components within
Strangvac. No adverse events related to the administration of
Strangvac or placebo control vaccines occurred; only mild side
effects listed above were noted.
3.2. Strangvac was immunogenic
The vaccination schedules for the studies and numbers of
ponies used are shown in Fig. 1 and Table 1, respectively. Twelve
ponies were vaccinated with Strangvac on days 0 and 28 in Exper-
iment I. Four of these ponies received a booster vaccination on day
119 (13 weeks post-second vaccination, group 1), four on day 210
(26 weeks post-second vaccination, group 2), and he remaining
four ponies were boosted on day 392 (52 weeks post-second vac-
cination, group 3) (Fig. 2) Antibody responses to all three vaccine
components in serum and nasal swab samples were significantly
elevated from 8 days post-first vaccination. We have previously
observed that this reflects an antibody response against each indi-
vidual component of the fusion proteins (Flock et al., unpublished
data). Antibody responses were boosted following the administra-
tion of the second vaccination on day 28 and third vaccination
whether this was given at 13, 26 or 52 weeks post-second vaccina-
tion. A gradual decline of antibody levels over time was observed,
which was quicker for nasal than for serum antibodies. However,
nasal antibody levels remained elevated for at least 100 days
post-second vaccination. These data provide evidence that the
administration of a third vaccination at up to 52 weeks post-
second vaccination induced antibody responses in sera and nasal
secretions that were equivalent to those obtained following the
second vaccination. Therefore, immune memory cells, which were
induced following the primary course of two vaccinations per-
sisted for at least a period of one year.
Data from the vaccination and challenge studies of Experiments
II, III and IV provide further evidence in support of the
Table 2
Combined injection site reaction data during vaccination phases. P values are calculated using the two sided Fisher’s exact test. V1, V2 and V3 is first, second and third vaccination,
respectively.
Vaccination point
Injection site measure Pony vaccination V1 P value V2 P value V3 P value
Heat > 1 Placebo-vaccinated 4/36 1 1/36 <0.001 1/15* <0.001
Strangvac-vaccinated 7/56 18/56 17/28
Pain Placebo-vaccinated 6/36 1 3/36 <0.001 1/15* 0.0012
Strangvac-vaccinated 9/56 24/56 16/28
Swelling Placebo-vaccinated 8/36 0.8 3/36 <0.001 2/15* <0.001
Strangvac-vaccinated 14/56 27/56 20/28
Fig. 2. Antibody levels in serum and nasal wash samples collected from ponies in EXP I for groups A and B. Log10 dilution of antibody levels in serum (A. CCE, B. Eq85 and C.
IdeE) and nasal wash samples (D. CCE, E. Eq85 and F. IdeE) for vaccination groups 1, 2 and 3 collected during vaccination in study EXP I. Error bars show standard deviation.
Open circles: group 1. Grey circles: group 2. Filled circles: group 3. Vaccination time points are indicated by open diamond: V1 groups 1, 2 and 3. Grey diamond: V2 groups 1,
2 and 3. Open triangle: V3 group 1. Grey triangle: V3 group 2. Filled triangle: V3 group 3. The third vaccination was given 13, 26 and 52 weeks after V2 in groups 1, 2 and 3,
respectively.
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against the vaccine components were detected in all of the ponies
that received Strangvac, with the earliest responses detected 7 days
post-first vaccination. The administration of the second vaccina-
tion on day 28 consistently boosted antibody responses to the vac-
cine components of Strangvac-, but not placebo-vaccinated ponies.
A similar increase in antibody levels was observed post-third vac-
cination on day 119 (13 weeks post-second vaccination) in Exper-
iment IV (Fig. S1). We conclude that the intramuscular
administration of Strangvac consistently induced the production
of antibodies against the vaccine components in all animals. A
large proportion of antibodies in mucosa may be due to transuda-
tion of plasma IgG through the mucosa. However, when comparing
antibody response in sera against mucosal response, no correlation
was found (data not shown) implying independent responses in
sera and mucosa. The induction of mucosal antibody responses
and protection against challenge following the intramuscular vac-
cination of horses with vaccines against equine herpes virus 1 or
equine influenza virus has been demonstrated previously [19,20].
3.3. Strangvac induced protection within two-weeks post-second
vaccination
In Experiment II, 32 ponies were given two intramuscular injec-
tions consisting of either Strangvac or the placebo control vaccine
(Fig. 1). Ponies were challenged 14 days post-second vaccinationby the administration of 1  108 colony forming units (cfu) of
Se4047 and monitored closely for the onset of clinical signs of
disease.
Five of 16 Strangvac vaccinated ponies reached the end of the
study at day 21 post-challenge, the primary end-point, without
developing pyrexia (defined as a rectal temperature of 39.0 C or
above that occurs on two out of three consecutive days post-
challenge), whilst all 16 of the placebo vaccinated ponies became
pyretic P = 0.04. The mean time to the onset of pyrexia for
Strangvac-vaccinated ponies was 13.6 days, compared to a mean
of 4.3 days for control ponies (P = 0.0001) (Fig. 3A and B).
Strangvac-vaccinated ponies also benefitted from a significant
reduction in the levels of fibrinogen (Fig. 3C) measured on day 8
post-challenge (5.7 g L1 compared to 11.8 g L1 (P < 0.0001) and
neutrophils counts (Fig. 3D) on day 8, 7.6  109 cells L1 compared
to 13.6  109 cells L1 (P < 0.0001). At day 8 post-challenge, three
of 16 Strangvac-vaccinated ponies had developed elevated levels of
fibrinogen compared with 14 of 16 controls (P = 0.0002) and 2
Strangvac-vaccinated ponies had developed elevated neutrophil
levels compared with 12 controls (P = 0.001). Although 14
Strangvac-vaccinated ponies developed at least one lymph node
abscess, the overall level of pathology observed at post-mortem
examination was significantly reduced in those ponies that had
received Strangvac (P = 0.006) (Fig. 3E). The occurrence of elevated
lymph node score (P = 0.001), swallow score (P = 0.04), feeding
score (P = 0.0434) and demeanour score (P = 0.04) were also
Fig. 3. Pyrexia, average rectal temperature, fibrinogen, neutrophil and post-mortem data in Experiment II. (A) Time to onset of pyrexia. (B) Average rectal temperatures up to
day 8, error bars indicate 95% confidence intervals. (C) Fibrinogen data for placebo and vaccinated ponies on day 8, boxes represent 10% and 90% percentiles, means are
represented by the horizontal bar, medians are represented by an *, and the error bars represent the standard error. D. Neutrophil data for placebo and vaccinated ponies on
days 8, boxes represent 10% and 90% percentiles, means are represented by the horizontal bar, medians are represented by an *, and the error bars represent the standard
error. E. Accumulated post mortem score of placebo and vaccinated ponies, medians are represented by a horizontal bar.
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tary table 1). We conclude that two doses of Strangvac significantly
delayed the onset and reduced the severity of disease induced by
challenge two-weeks post-second vaccination.
3.4. Strangvac protected ponies for at least two months post-second
vaccination
Experiment III was performed to determine the level of protec-
tion conferred by two doses of Strangvac two months after the
administration of the second vaccination (Fig. 1). Ponies were again
challenged by the administration of 1  108 cfu of Se4047 and
monitored closely for the onset of clinical signs of disease.
Seven of twelve ponies vaccinated with Strangvac (58%) did not
become pyretic post-challenge compared with all four ponies vac-
cinated with the placebo control vaccine (P = 0.09). Analysis on day
8 showed that Strangvac-vaccinated ponies had lower mean rectal
temperatures (38.6 C compared to 40.2 C), mean ocular score (0.8
compared to 2.5, P = 0.1), mean nasal score (0.3 compared to 2.0,
P = 0.13) and mean coughing score (0.2 compared to 1.0,
P = 0.004). Strangvac-vaccinated ponies also had lower mean swal-
low score (0.3 compared to 1.0, P = 0.03), mean feeding score (0.3
compared to 1.3, P = 0.07) and mean demeanour score (0.2compared to 1.5, P = 0.01) when compared to placebo-vaccinated
controls. The mean time to onset of pyrexia for Strangvac-
vaccinated ponies was 14.3 days, compared to a mean of 3.5 days
for controls. Fibrinogen and neutrophil levels on day 8 post-
challenge were reduced in Strangvac vaccinated ponies: 7.6 g L1
compared to 12.1 g L1 (P = 0.002) and 9.4  109 cells L1 com-
pared to 13.3  109 cells L1 (P = 0.02), respectively (measured
on day 8). All 4 control ponies developed at least one lymph node
abscess compared to 6 of the 12 Strangvac-vaccinated ponies. The
post-mortem score was also reduced in Strangvac-vaccinated
ponies with a mean PM score of 17.2 in vaccinates and 49 in con-
trols (P = 0.006). We conclude that the vaccination of ponies with
Strangvac reduced the amount of clinical disease induced by chal-
lenge with Se4047 two-months post-second vaccination.
3.5. Strangvac conferred excellent levels of protection following re-
vaccination of ponies
In Experiment IV, 32 ponies were vaccinated with Strangvac or
a placebo control vaccine, followed by a second dose 4 weeks post-
first vaccination and a third dose 13 weeks post-second vaccina-
tion (Fig. 1). Ponies were challenged by the administration of
1  108 cfu of Se4047 two weeks post-third vaccination and
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the placebo-vaccinated control ponies suffered a serious adverse
event on day 98, which was unrelated to the study, and was
removed from the analysis.
Of the 31 ponies that received the challenge, all 15 placebo
control-vaccinated ponies became pyretic compared to only one of
the 16 Strangvac-vaccinated ponies (P < 0.0001). The mean time to
onset of pyrexia for Strangvac-vaccinated ponies was 20 days, com-
pared to amean of 6 days for controls (P < 0.0001) (Fig. 4A and B). On
day 8 post-challenge, Strangvac-vaccinated ponies showed a highly
significant reduction in the levels of fibrinogen (4.1 g L1 compared
to 12.6 g L1; P < 0.0001) and neutrophils (5.5  109 cells L1 com-
pared to 12.3  109 cells L1; P < 0.0001) (Fig. 4C and D). One
Strangvac-vaccinated pony developed elevated levels of fibrinogen
compared with all 15 controls (P < 0.0001) and one Strangvac-
vaccinated pony developed elevated neutrophil levels compared
with 12 controls (P < 0.0001). Fourteen of the 15 control ponies
developed at least one lymph node abscess identified at post-
mortem examination compared to one Strangvac-vaccinated pony
(P < 0.0001). The mean level of pathology score observed at
post-mortem examination was significantly reduced inFig. 4. Pyrexia, fibrinogen, neutrophil and post-mortem data in experiment IV. (A) Time
95% confidence intervals. (C) Fibrinogen data for placebo and vaccinated ponies on day 8
bar, medians are represented by an *, and the error bars represent the standard error. (D) N
90% percentiles means are represented by the horizontal bar, medians are represented by
score of placebo and vaccinated ponies, medians are represented by a horizontal bar.Strangvac-vaccinated ponies, 5.3 compared to 54.1 (P < 0.0001)
(Fig. 4E). S. equi was detected by qPCR of swab samples taken
post-mortem from three of 16 Strangvac-vaccinated ponies com-
pared to swab samples from all 15 control ponies (P < 0.0001).
Strangvac-vaccinated ponies also had significantly reduced inci-
dence of elevated lymph node score (P = 0.0008), coughing score
(P < 0.0001), swallow score (P < 0.0001), feeding score (P < 0.0001)
and demeanour score (P < 0.0001) (Supplementary table 2).We con-
clude that Strangvac conferred excellent levels of protection against
challenge with S. equi two-weeks post-third vaccination.
The protection conferred by Strangvac appeared to be higher at
two months post-second vaccination rather than at two weeks
post-second vaccination, despite a decline in the antibody response
to vaccine components over this period (Fig. S1). Similarly, highest
levels of protection were observed at two weeks post-third vacci-
nation, despite the antibody response being at the same level as
that obtained at two weeks post-second vaccination. It is thus pos-
sible that, in addition to antibody response, Strangvac induces an
as yet undetermined cell-mediated immune response, which may
reduce the ability of S. equi to infect the lymph nodes of the head
and neck.to onset of pyrexia. (B) Average rectal temperatures up to day 8, error bars indicate
, boxes represent 10% and 90% percentiles, means are represented by the horizontal
eutrophil data for placebo and vaccinated ponies on day 8, boxes represent 10% and
an *, and the error bars represent the standard error. (E) Accumulated post mortem
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The data obtained from placebo control vaccinated ponies that
were challenged in Experiment II (16 ponies), III (4 ponies) and
IV (15 ponies) were analysed to determine if there was a statisti-
cally significant difference between these groups. Comparison of
the time to pyrexia for the control groups of ponies in each of
the studies identified that there was no significant difference
between the studies (P = 0.15) (supplementary Fig. 2a). Compar-
ison of the pool of placebo control data from Experiments II and
IV to the four control ponies in Experiment III did not identify a sta-
tistical difference (P = 0.94). Similarly, there was no significant dif-
ference in the pathology score obtained from the three groups of
control ponies at post-mortem examination (P = 0.88) (supplemen-
tary Fig. 2b) or from the pool of placebo controls compared to the
controls in EXP III (P = 0.66). This supports the view that the infec-
tion model used in these studies is robust and reproducible.3.7. The use of pooled control data can reduce the number of ponies
required
Three groups (groups 1–3) of eight placebo vaccinated control
ponies were constructed by random selection from studies Exper-
iment II (16 ponies) and IV (15 ponies). Data from these three
groups were then each added to the Experiment III analysis and
used to recalculate the level of statistical significance in an other-
wise underpowered study. Plotting the average rectal temperature
data for Strangvac vaccinated and control ponies (Fig. 5) showed
that the addition of pooled control data from groups 1–3 (Fig. 5,
panels B, C and D) did not alter the onset or severity of pyrexia
compared with the original EXP III control data (Fig. 5, panel A).
All of the control ponies in the pools from Experiment IV and II
became pyretic post-challenge. Therefore, the addition of any ofFig. 5. Rectal temperatures using pooled control ponies. Average rectal temperature pos
control ponies in EXP III. (B) the original 4 control ponies in EXP III plus historical data fro
data from 8 pool 2 control ponies. (D) the original 4 control ponies in EXP III plus historthe three pooled control samples showed a statistically significant
difference in the incidence of pyrexia between Strangvac-
vaccinated in Experiment III and the placebo control-vaccinated
groups (all P = 0.005), regardless of which control ponies were
selected as controls in the pools. The addition of pooled control
data confirmed the significance of post-mortem pathology score
data (all P < 0.0001) (Fig. 6). We conclude that the challenge of
Welsh mountain ponies with a dose of 1  108 cfu of Se4047 con-
sistently induces clinical signs that reproduce the natural disease.
Large numbers of control ponies are often required for each study
to ‘stand-alone’ and reach statistical significance. Therefore, the
use of pooled data from placebo vaccinated control ponies is an
effective approach to reduce the number of ponies required in
accordance with the principles of the 3Rs.3.8. Correlation between different clinical observation parameters
The discrimination between infected and non-infected animals
was based on the definition of pyrexia as an elevated rectal tem-
perature (>38.9 C) for two days during any three-day period. This
definition as a predictor of disease is justified by its significant cor-
relation with post-mortem score (P < 0.001), combined clinical
score (P < 0.001), fibrinogen level (P < 0.001) and neutrophil count
(P < 0.001) as assessed on day 8 post-challenge.3.9. Strangvac has DIVA capability
The analysis using a commercial dual antigen iELISA [6] of
serum samples that were collected after vaccination with Strang-
vac, but pre-challenge, demonstrated that the vaccination of
ponies with Strangvac did not interfere with this widely-used diag-
nostic assay. Furthermore, none of the Strangvac-vaccinated ponies
returned a positive qPCR test result pre-challenge using a triplext-challenge for the 12 Strangvac vaccinated ponies compared to: (A) the original 4
m 8 pool 1 control ponies. (C) the original 4 control ponies in EXP III plus historical
ical data from 8 pool 3 control ponies. Error bars indicate 95% confidence intervals.
Fig. 6. Pathology scores utilising pooled control ponies. Pathology scores for the 12
Strangvac vaccinated ponies compared to: the original 4 control ponies in EXP III,
the original 4 control ponies in EXP III plus historical data from 8 pool 1 control
ponies, the original 4 control ponies in EXP III plus historical data from 8 pool 2
control ponies and the original 4 control ponies in EXP III plus historical data from 8
pool 3 control ponies. P values are indicated.
4868 C. Robinson et al. / Vaccine 38 (2020) 4861–4868qPCR assay [4]. Eight of 32 ponies in EXP II seroconverted to the
dual antigen iELISA [6] and 15 tested positive for S. equi DNA
post-challenge. We conclude that Strangvac had DIVA capability,
which will be invaluable for the use of this vaccine in populations
of horses where infection with S. equi is endemic.
4. Final conclusions
We provide strong evidence in support of the use of convenient
intramuscular vaccination with Strangvac for the prevention of
experimentally induced strangles in horses. The vaccine was safe,
immunogenic and effective, particularly at two-weeks post-third
vaccination. Furthermore, Strangvac has DIVA capability enabling
this vaccine to be used alongside conventional disease prevention
strategies for the first time. Therefore, Strangvac is likely to play a
significant role in the prevention of strangles in horses, in particu-
lar through the re-vaccination of horses following the identifica-
tion of an index case or prior to the transportation of an animal
to equine events where there is a risk of exposure to S. equi. It is
particularly noteworthy that immune memory cells persist over a
period of at least a year, justifying a booster at any time during this
period, in previously primed horses, at a situation where the risk of
exposure is enhanced.
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